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I read with interest the case report by Narayanan et al.1 on
cryptococcal immune reconstitution inﬂammatory syndrome
(IRIS) during steroid withdrawal. Corticosteroids are known to
depress the host response by suppression of the inﬂammatory
response. Treatment with corticosteroids has been shown to be the
common underlying condition predisposing to cryptococcosis in
non-HIV-infected patients.2–5 We also had a patient at our
institution who, after treatment with prednisone for nephrotic
syndrome for 2 years, developed cryptococcal meningitis. Predni-
sone was discontinued after she was diagnosed. After 4 weeks of
amphotericin B combined with ﬂucytosine therapy, the patient’s
symptoms (fever, headache, vomiting, blindness) improved
signiﬁcantly; her cerebrospinal ﬂuid pressure decreased from
400 mmH2O to 180 mmH2O and cryptococcal antigen titer
declined from 1:256 to 1:32. However, on day 40 of treatment
her condition deteriorated rapidly, manifested as headache,
vomiting, sepsis syndrome with sterile cultures, cerebrospinal
ﬂuid pleocytosis, increasing intracranial pressure, and cultures
that were negative for Cryptococcus neoformans. All this was not
explained by any newly acquired infection. We suspected IRIS, but
the patient was discharged because of the family’s refusal to
continue therapy.
IRIS is characterized by a paradoxical worsening of treated
opportunistic infections due to the recovery of the immune system
when factors promoting immunosuppression or inhibiting inﬂam-
mation are rapidly decreased or removed. IRIS is now well-
recognized among HIV-infected patients, and several diagnostic
criteria for a case deﬁnition have already been published.6
Clinicians most commonly pay attention to the HIV-infected
patients who initiate antiretroviral therapy or to transplant
recipients reducing their immunosuppression therapy. IRIS is also
seen in other immunocompromised hosts, but there is insufﬁcient
data about this entity in non-HIV-infected patients.1,7–9 The
concept of IRIS in HIV-negative patients and its diagnosis in the
context of opportunistic mycoses remains poorly characterized for
healthcare providers. In the case reported by Narayanan et al.1 and
in our case, both patients underwent a rapid reduction or
withdrawal of steroids after diagnosis of cryptococcosis, and
received an effective antifungal therapy. Both antimicrobial use
and rapid reduction or withdrawal of immunosuppressive agents
might predispose to the development of IRIS in solid organ
transplant recipients.10 Hypercalcemia associated with granulo-
matous inﬂammatory reactions may play an important role in the
diagnosis of this condition. But without a description and1201-9712/$36.00 – see front matter  2011 International Society for Infectious Disea
doi:10.1016/j.ijid.2011.09.001established diagnostic criteria for non-HIV-infected patients, IRIS
is easily construed as a failure of therapy or a relapse caused by the
patient’s inability to eliminate the pathogens, leading to unwar-
ranted or inappropriate changes in treatment. Diagnosis and
management of IRIS in non-HIV-infected patients poses great
challenges for care providers, so more clinical investigations are
needed to support a deﬁnitive conclusion.
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